Optimal therapeutic strategy using durable left ventricular assist device in Korea
Lee and colleagues reported the first experience of durable left ventricular assist device (LVAD) implantation before the initiation of Korean national insurance coverage in 2018 (1). I would like to congratulate their successful LVAD therapy with favorable outcomes comparable to those reported in the international registry, despite relatively sick cohort with contraindication of heart transplantation. Several concerns should improve their findings.
Because all LVAD implantations were performed before the approval of Korean national insurance, patient profiles were unique (1). Now that medical insurance covers LVAD implantation, optimal patient selection, including preserved end-organ dysfunction and relatively stable hemodynamics assigned to INTERMACS profile 3, might be required to further improve clinical outcomes.
As device-related comorbidity, aortic insufficiency is one of the critical and progressive diseases that increase intra-cardiac loading and worsen systemic congestion (2). Repeated trans-thoracic echocardiography or monitoring of HeartWare waveform would be useful for early detection and follow-up of aortic insufficiency (3). The incidence of gastrointestinal bleeding was relatively high (1). Given the low incidence of gastrointestinal bleeding in Japan, we hypothesized that Asian patients might have a genetic resistance to gastrointestinal bleeding (4). Further studies are warranted to investigate the association between genetic type and bleeding complication.
Almost half of clinically stable LVAD patients have abnormal hemodynamics, which is associated with device-related comorbidities (5). Our team proposed a hemodynamic ramp test, during which medication and device speed are optimized considering hemodynamic profiles at each device speed, targeting to improve mortality and morbidity. Description of hemodynamic management in their team would strengthen the implication of their report.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was a standard submission to the journal. The article did not undergo external peer review.
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-21-125). TI reports grant support from JSPS KAKENHI: JP20K17143.
Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Lee JH, Park I, Lee H, et al. Use of durable left ventricular assist devices for high-risk patients: Korean experience before insurance coverage. J Thorac Dis 2020;12:7236-44. [Crossref] [PubMed]
- Imamura T, Kinugawa K, Fujino T, et al. Aortic insufficiency in patients with sustained left ventricular systolic dysfunction after axial flow assist device implantation. Circ J 2015;79:104-11. [Crossref] [PubMed]
- Imamura T, Narang N, Rodgers D, et al. Estimation of the severity of aortic insufficiency by HVAD flow waveform. Ann Thorac Surg 2020;109:945-9. [Crossref] [PubMed]
- Imamura T, Ono M, Kinugawa K, et al. Hemocompatibility-related adverse events following HeartMate II left ventricular assist device implantation between Japan and United States. Medicina (Kaunas) 2020;56:126. [Crossref] [PubMed]
- Uriel N, Sayer G, Addetia K, et al. Hemodynamic ramp tests in patients with left ventricular assist devices. JACC Heart Fail 2016;4:208-17. [Crossref] [PubMed]
